Autoimmune B-cell lymphopenia after successful adoptive therapy with telomerase-specific T lymphocytes

Stefano Ugel, Elisa Scarselli, Manuela Iezzi, Carmela Mennuni, Tania Pannellini, Francesco Calvaruso, Barbara Cipriani, Raffaele De Palma, Lucia Ricci-Vitiani, Elisa Peranzoni, Piero Musiani, Paola Zanovello, Vincenzo Bronte

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Telomerase reverse transcriptase (TERT) is a good candidate for cancer immunotherapy because it is overexpressed in 85% of all human tumors and implicated in maintenance of the transformed phenotype. TERT-based cancer vaccines have been shown to be safe, not inducing any immune-related pathology, but their impact on tumor progression is modest. Here we show that adoptive cell therapy with the use of high-avidity T lymphocytes reactive against telomerase can control the growth of different established tumors. Moreover, in transgenic adenocarcinoma mouse prostate mice, which develop prostate cancer, TERT-based adoptive cell therapy halted the progression to more aggressive and poorly differentiated tumors, significantly prolonging mouse survival.We also demonstrated that human tumors, including Burkitt lymphoma, and human cancer stem cells, are targeted in vivo by TERT-specific cytotoxic T lymphocytes. Effective therapy with T cells against telomerase, different from active vaccination, however, led to autoimmunity marked by a consistent, although transient, B-cell depletion in primary and secondary lymphoid organs, associated with alteration of the spleen cytoarchitecture. These results indicate B cells as an in vivo target of TERT-specific cytotoxic T lymphocytes during successful immunotherapy.

Original languageEnglish
Pages (from-to)1374-1384
Number of pages11
JournalBlood
Volume115
Issue number7
DOIs
Publication statusPublished - Feb 18 2010

Fingerprint

Lymphopenia
T-cells
Telomerase
B-Lymphocytes
Cells
T-Lymphocytes
Tumors
Neoplasms
Cytotoxic T-Lymphocytes
Cell- and Tissue-Based Therapy
Immunotherapy
Therapeutics
Cancer Vaccines
Burkitt Lymphoma
Neoplastic Stem Cells
Pathology
Stem cells
Autoimmunity
Transgenic Mice
Prostate

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Ugel, S., Scarselli, E., Iezzi, M., Mennuni, C., Pannellini, T., Calvaruso, F., ... Bronte, V. (2010). Autoimmune B-cell lymphopenia after successful adoptive therapy with telomerase-specific T lymphocytes. Blood, 115(7), 1374-1384. https://doi.org/10.1182/blood-2009-07-233270

Autoimmune B-cell lymphopenia after successful adoptive therapy with telomerase-specific T lymphocytes. / Ugel, Stefano; Scarselli, Elisa; Iezzi, Manuela; Mennuni, Carmela; Pannellini, Tania; Calvaruso, Francesco; Cipriani, Barbara; De Palma, Raffaele; Ricci-Vitiani, Lucia; Peranzoni, Elisa; Musiani, Piero; Zanovello, Paola; Bronte, Vincenzo.

In: Blood, Vol. 115, No. 7, 18.02.2010, p. 1374-1384.

Research output: Contribution to journalArticle

Ugel, S, Scarselli, E, Iezzi, M, Mennuni, C, Pannellini, T, Calvaruso, F, Cipriani, B, De Palma, R, Ricci-Vitiani, L, Peranzoni, E, Musiani, P, Zanovello, P & Bronte, V 2010, 'Autoimmune B-cell lymphopenia after successful adoptive therapy with telomerase-specific T lymphocytes', Blood, vol. 115, no. 7, pp. 1374-1384. https://doi.org/10.1182/blood-2009-07-233270
Ugel S, Scarselli E, Iezzi M, Mennuni C, Pannellini T, Calvaruso F et al. Autoimmune B-cell lymphopenia after successful adoptive therapy with telomerase-specific T lymphocytes. Blood. 2010 Feb 18;115(7):1374-1384. https://doi.org/10.1182/blood-2009-07-233270
Ugel, Stefano ; Scarselli, Elisa ; Iezzi, Manuela ; Mennuni, Carmela ; Pannellini, Tania ; Calvaruso, Francesco ; Cipriani, Barbara ; De Palma, Raffaele ; Ricci-Vitiani, Lucia ; Peranzoni, Elisa ; Musiani, Piero ; Zanovello, Paola ; Bronte, Vincenzo. / Autoimmune B-cell lymphopenia after successful adoptive therapy with telomerase-specific T lymphocytes. In: Blood. 2010 ; Vol. 115, No. 7. pp. 1374-1384.
@article{b7b431c6af024a70ac66b8c4368d2537,
title = "Autoimmune B-cell lymphopenia after successful adoptive therapy with telomerase-specific T lymphocytes",
abstract = "Telomerase reverse transcriptase (TERT) is a good candidate for cancer immunotherapy because it is overexpressed in 85{\%} of all human tumors and implicated in maintenance of the transformed phenotype. TERT-based cancer vaccines have been shown to be safe, not inducing any immune-related pathology, but their impact on tumor progression is modest. Here we show that adoptive cell therapy with the use of high-avidity T lymphocytes reactive against telomerase can control the growth of different established tumors. Moreover, in transgenic adenocarcinoma mouse prostate mice, which develop prostate cancer, TERT-based adoptive cell therapy halted the progression to more aggressive and poorly differentiated tumors, significantly prolonging mouse survival.We also demonstrated that human tumors, including Burkitt lymphoma, and human cancer stem cells, are targeted in vivo by TERT-specific cytotoxic T lymphocytes. Effective therapy with T cells against telomerase, different from active vaccination, however, led to autoimmunity marked by a consistent, although transient, B-cell depletion in primary and secondary lymphoid organs, associated with alteration of the spleen cytoarchitecture. These results indicate B cells as an in vivo target of TERT-specific cytotoxic T lymphocytes during successful immunotherapy.",
author = "Stefano Ugel and Elisa Scarselli and Manuela Iezzi and Carmela Mennuni and Tania Pannellini and Francesco Calvaruso and Barbara Cipriani and {De Palma}, Raffaele and Lucia Ricci-Vitiani and Elisa Peranzoni and Piero Musiani and Paola Zanovello and Vincenzo Bronte",
year = "2010",
month = "2",
day = "18",
doi = "10.1182/blood-2009-07-233270",
language = "English",
volume = "115",
pages = "1374--1384",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "7",

}

TY - JOUR

T1 - Autoimmune B-cell lymphopenia after successful adoptive therapy with telomerase-specific T lymphocytes

AU - Ugel, Stefano

AU - Scarselli, Elisa

AU - Iezzi, Manuela

AU - Mennuni, Carmela

AU - Pannellini, Tania

AU - Calvaruso, Francesco

AU - Cipriani, Barbara

AU - De Palma, Raffaele

AU - Ricci-Vitiani, Lucia

AU - Peranzoni, Elisa

AU - Musiani, Piero

AU - Zanovello, Paola

AU - Bronte, Vincenzo

PY - 2010/2/18

Y1 - 2010/2/18

N2 - Telomerase reverse transcriptase (TERT) is a good candidate for cancer immunotherapy because it is overexpressed in 85% of all human tumors and implicated in maintenance of the transformed phenotype. TERT-based cancer vaccines have been shown to be safe, not inducing any immune-related pathology, but their impact on tumor progression is modest. Here we show that adoptive cell therapy with the use of high-avidity T lymphocytes reactive against telomerase can control the growth of different established tumors. Moreover, in transgenic adenocarcinoma mouse prostate mice, which develop prostate cancer, TERT-based adoptive cell therapy halted the progression to more aggressive and poorly differentiated tumors, significantly prolonging mouse survival.We also demonstrated that human tumors, including Burkitt lymphoma, and human cancer stem cells, are targeted in vivo by TERT-specific cytotoxic T lymphocytes. Effective therapy with T cells against telomerase, different from active vaccination, however, led to autoimmunity marked by a consistent, although transient, B-cell depletion in primary and secondary lymphoid organs, associated with alteration of the spleen cytoarchitecture. These results indicate B cells as an in vivo target of TERT-specific cytotoxic T lymphocytes during successful immunotherapy.

AB - Telomerase reverse transcriptase (TERT) is a good candidate for cancer immunotherapy because it is overexpressed in 85% of all human tumors and implicated in maintenance of the transformed phenotype. TERT-based cancer vaccines have been shown to be safe, not inducing any immune-related pathology, but their impact on tumor progression is modest. Here we show that adoptive cell therapy with the use of high-avidity T lymphocytes reactive against telomerase can control the growth of different established tumors. Moreover, in transgenic adenocarcinoma mouse prostate mice, which develop prostate cancer, TERT-based adoptive cell therapy halted the progression to more aggressive and poorly differentiated tumors, significantly prolonging mouse survival.We also demonstrated that human tumors, including Burkitt lymphoma, and human cancer stem cells, are targeted in vivo by TERT-specific cytotoxic T lymphocytes. Effective therapy with T cells against telomerase, different from active vaccination, however, led to autoimmunity marked by a consistent, although transient, B-cell depletion in primary and secondary lymphoid organs, associated with alteration of the spleen cytoarchitecture. These results indicate B cells as an in vivo target of TERT-specific cytotoxic T lymphocytes during successful immunotherapy.

UR - http://www.scopus.com/inward/record.url?scp=77949905159&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949905159&partnerID=8YFLogxK

U2 - 10.1182/blood-2009-07-233270

DO - 10.1182/blood-2009-07-233270

M3 - Article

C2 - 19903903

AN - SCOPUS:77949905159

VL - 115

SP - 1374

EP - 1384

JO - Blood

JF - Blood

SN - 0006-4971

IS - 7

ER -